FLT3 and acute myeloid leukemia: Approximately 30% of newly diagnosed AML ensues from mutations in FLT3, which are divided into two classes: internal tandem duplications (FLT3–ITD)—which involve the juxtamembrane domain, and the second class: tyrosine kinase domain mutations (FLT3–TKD) [48,52,53].